The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis

Written by Regenerative Medicine

In this Regenerative Medicine Special Report, learn more about the US direct-to-consumer marketplace for stem cell interventions. Hundreds of businesses in the US currently advertise a wide range of non-US FDA-approved stem cell interventions. In this Regenerative Medicine Special Report, Paul S Knoepfler and Leigh G Turner present a novel systematic temporal analysis of US companies engaged in direct-to-consumer marketing of putative stem cell treatments. Between 2009 and 2014, the number of new US stem cell businesses with websites grew rapidly, at least doubling on average every year. From 2014 to 2016, approximately 90-100 new stem cell business websites appeared...

To view the full article, please register now for access

It's completely free